Hyperkalemia in Adults

Quick Reference

Critical Alerts

Hyperkalemia is a life-threatening emergency that kills by cardiac arrhythmia

• Peaked T waves → Wide QRS → Sine wave → VF/Asystole: ECG changes progress rapidly and unpredictably [1]
• ECG changes require immediate treatment regardless of potassium level: Calcium gluconate FIRST for membrane stabilization [2]
• Severe hyperkalemia (> 6.5 mEq/L or ANY ECG changes) is an emergency: Immediate multi-modal therapy required [3]
• Treatment sequence is critical: Stabilize membrane → Shift K+ intracellularly → Remove K+ from body [4]
• Pseudohyperkalemia is common: Hemolyzed samples, difficult venipuncture, thrombocytosis, leukocytosis [5]
• Dialysis is definitive for severe/refractory hyperkalemia: Most effective potassium removal method [6]
• Recurrent hyperkalemia increases mortality: Associated with 2-3× increased cardiovascular mortality risk [7]

ECG Changes in Hyperkalemia (Progressive Cardiotoxicity)

Critical Concept: ECG changes do NOT always correlate with serum K+ level - some patients develop severe arrhythmias at K+ 6.0 mEq/L while others tolerate 7.5 mEq/L [8]

Emergency Treatment Protocol (Execute Sequentially)

Time-Critical Interventions [9,10]

CRITICAL NOTES:

• Calcium does NOT lower potassium - it only protects the heart
• Repeat calcium gluconate 10 mL after 5 minutes if ECG changes persist [2]
• Monitor glucose every 30-60 minutes with insulin therapy (hypoglycemia risk) [11]
• Combine insulin-dextrose + salbutamol for additive effect (1.2-1.4 mEq/L reduction) [12]
• Bicarbonate is NOT effective in non-acidotic patients [13]

---

Definition and Classification

Overview

Hyperkalemia is defined as serum potassium concentration > 5.5 mEq/L (> 5.5 mmol/L). It represents a potentially life-threatening electrolyte disorder due to its profound effects on cardiac electrical conduction and neuromuscular function. [1,14]

Pathophysiological Principle: Normal cellular function depends on the potassium gradient across cell membranes (intracellular K+ ~140 mEq/L vs. extracellular K+ 3.5-5.0 mEq/L). This gradient determines resting membrane potential and excitability of cardiac and skeletal muscle. [15]

Classification by Severity

Important: Absolute K+ level is less important than ECG changes and rate of rise. Rapid increases are more dangerous than chronic hyperkalemia. [8]

---

Epidemiology and Risk Factors

Incidence and Prevalence

• General hospitalized patients: 1-10% prevalence [16]
• Emergency department presentations: 1-2.5% of all patients [3]
• Chronic kidney disease (CKD):
  • "CKD Stage 3-4: 2-3% prevalence"
  • "CKD Stage 5/ESRD: 5-10% prevalence between dialysis sessions [17]"
• Heart failure patients on RAAS inhibitors: 5-15% develop hyperkalemia [18]
• Intensive care units: 5-10% of critically ill patients [19]

Mortality and Outcomes

Hyperkalemia is associated with significant morbidity and mortality [7,20]:

• In-hospital mortality:
  • "K+ 5.5-6.0 mEq/L: 1-2% mortality"
  • "K+ 6.0-7.0 mEq/L: 5-10% mortality"
  • "K+ > 7.0 mEq/L: 20-40% mortality"
• Recurrent hyperkalemia: Associated with 2-3× increased risk of cardiovascular mortality and all-cause mortality [7]
• RAAS inhibitor discontinuation due to hyperkalemia: Increases risk of heart failure hospitalization and death [21]
• Sudden cardiac death: Risk increases exponentially with K+ > 6.0 mEq/L [22]

High-Risk Populations

---

Etiology and Pathophysiology

Mechanisms of Hyperkalemia

Hyperkalemia results from one or more of the following mechanisms [14,23]:

1. Increased potassium intake (rarely sole cause unless renal impairment)
2. Decreased renal potassium excretion (most common)
3. Transcellular potassium shift (K+ moves from ICF to ECF)
4. Pseudohyperkalemia (falsely elevated measurement)

1. Increased Potassium Intake

Rarely causes hyperkalemia in patients with normal renal function (kidneys can excrete 10× normal intake)

2. Decreased Renal Excretion (MOST COMMON CAUSE)

Normal K+ homeostasis: 90% of K+ excretion is renal (10% GI). Principal cells in collecting duct secrete K+ under aldosterone influence. [24]

A. Reduced Glomerular Filtration Rate

B. Impaired Tubular Potassium Secretion

Medications Affecting RAAS (MOST COMMON DRUG-INDUCED CAUSE) [21,25]

Dual/Triple RAAS Blockade: Combination therapy dramatically increases risk (ACEi + ARB or + spironolactone) [26]

Endocrine/Tubular Disorders

3. Transcellular Potassium Shift (ICF → ECF)

Principle: 98% of total body K+ is intracellular. Small shifts cause large changes in serum K+. [15]

Metabolic Acidosis Effect: Each 0.1 unit ↓ in pH → ~0.6 mEq/L ↑ in serum K+ (ONLY for non-organic acidosis like mineral acids; does NOT apply to lactic acidosis or ketoacidosis) [27]

4. Pseudohyperkalemia (False Elevation)

Definition: Artifactually elevated serum K+ due to in vitro K+ release from cells during or after blood collection [5]

Diagnosis: Plasma K+ (not serum) will be normal; no ECG changes; patient asymptomatic

---

Molecular Pathophysiology: Cardiac Conduction Effects

Normal Cardiac Electrophysiology

Resting Membrane Potential (RMP): Determined primarily by K+ gradient across cell membrane [15]

• Nernst equation: RMP ≈ -61 × log ([K+]intracellular / [K+]extracellular)
• Normal RMP: Approximately -90 mV (ventricular myocytes)
• K+ is the major determinant because resting membrane is highly permeable to K+

Effect of Hyperkalemia on Cardiac Cells

Phase 0 - Depolarization (Sodium Influx):

• Hyperkalemia → ↑ extracellular K+ → Less negative RMP (e.g., -90 mV becomes -80 mV)
• Cells closer to threshold → Increased excitability initially (paradoxical)
• BUT: Many Na+ channels become inactivated at less negative RMP
• Result: Slower Phase 0 upstroke → Slowed conduction velocity → Wide QRS

Phase 3 - Repolarization (Potassium Efflux):

• Hyperkalemia → ↑ K+ driving force for efflux → Faster repolarization
• Result: Shortened QT interval, peaked T waves

Progressive Depolarization:

• Severe hyperkalemia (> 7.0 mEq/L): RMP becomes critically depolarized
• Progressive Na+ channel inactivation → Extreme conduction slowing
• P wave disappears (atrial standstill)
• QRS progressively widens → Merges with T wave → Sine wave pattern
• Terminal arrhythmias: VF, slow idioventricular rhythm, asystole

Why Calcium Works (Membrane Stabilization)

Calcium's Protective Mechanism [2,28]:

1. Increases threshold potential (makes it more positive)
2. Increases distance between RMP and threshold → Harder to depolarize
3. Reduces membrane excitability despite persistent hyperkalemia
4. Does NOT change serum potassium - purely membrane effect
5. Effect is immediate (1-3 minutes) but temporary (30-60 minutes)

Clinical Implication: Calcium buys time for K+-lowering therapies to work

---

Clinical Presentation

Symptoms

Critical Concept: Hyperkalemia is often asymptomatic until severe. Patients may present with sudden cardiac arrest as first manifestation. [1,8]

Physical Examination

Most patients have normal examination - ECG is the key diagnostic test

Key History Elements

Essential Questions:

1. Renal history: Known CKD? Dialysis? Recent AKI? Urine output?
2. Medications: ACE/ARB? Spironolactone? NSAIDs? K+ supplements? Salt substitutes?
3. Dietary K+ intake: High-K+ foods? Nutritional supplements?
4. Tissue breakdown: Trauma? Seizures? Excessive exercise? Recent chemotherapy?
5. Endocrine: Adrenal insufficiency symptoms? Diabetes control?
6. Previous episodes: Recurrent hyperkalemia? Prior dialysis for K+?
7. Cardiac history: Arrhythmias? Pacemaker/ICD?

---

Electrocardiographic Findings

Progressive ECG Changes [1,8,29]

CRITICAL: ECG changes are the MOST IMPORTANT prognostic finding - more than absolute K+ level

Stage 1: Mild Hyperkalemia (K+ 5.5-6.5 mEq/L)

• Tall, peaked T waves with narrow base (earliest and most sensitive finding)
• Shortened QT interval (faster repolarization)
• Best seen in precordial leads (V2-V4)
• May be subtle - compare to prior ECG

Stage 2: Moderate Hyperkalemia (K+ 6.5-7.0 mEq/L)

• Prolonged PR interval (> 200 ms)
• Flattened or absent P waves (atrial paralysis)
• Continued peaked T waves
• Widening QRS begins (> 100 ms)

Stage 3: Severe Hyperkalemia (K+ 7.0-8.0 mEq/L)

• Wide QRS complex (> 120 ms) - OMINOUS SIGN
• Absent P waves (complete atrial standstill)
• Tall peaked T waves merge with wide QRS
• Deepened S waves
• ST segment depression possible

Stage 4: Critical Hyperkalemia (K+ > 8.0 mEq/L)

• Sine wave pattern (QRS merges completely with T wave)
• Progressive bradycardia
• Ventricular fibrillation or asystole imminent

ECG Mimics and Confounders

Important Variations:

• ECG changes may be absent even with K+ > 7.0 mEq/L (especially chronic hyperkalemia) [8]
• Calcium levels affect ECG manifestations: Hypocalcemia exacerbates ECG changes
• Acidosis and hyponatremia worsen conduction abnormalities
• Paced rhythms may mask hyperkalemia ECG changes

---

Diagnostic Approach

Initial Diagnostic Workup

ALL patients with suspected or confirmed hyperkalemia [3,30]

Excluding Pseudohyperkalemia [5]

High clinical suspicion when:

• Unexpected K+ elevation in asymptomatic patient
• Hemolyzed sample (pink/red serum)
• Platelet count > 500 × 10⁹/L or WBC > 100 × 10⁹/L
• No ECG changes despite K+ > 6.5 mEq/L
• Difficult blood draw (prolonged tourniquet, fist clenching)

Diagnostic Strategy:

1. Repeat sample from different site without tourniquet or fist clenching
2. Send plasma K+ (not serum) - no clotting → no platelet K+ release
3. Process rapidly (within 1 hour of collection)
4. Compare whole blood K+ vs. serum K+ (if available)

Assessing Renal Potassium Handling (Advanced)

When to assess: Unclear etiology + normal renal function (Cr less than 1.5 mg/dL)

Transtubular Potassium Gradient (TTKG)

Formula: TTKG = (Urine K+ × Plasma Osm) / (Plasma K+ × Urine Osm)

Interpretation (in hyperkalemia):

• TTKG less than 5: Appropriate renal K+ retention (hypoaldosteronism, Type 4 RTA, renal failure)
• TTKG > 7: Inappropriate renal K+ wasting despite hyperkalemia (suggests extrarenal cause)

Limitations: Requires urine Osm > 300 mOsm/kg and urine Na > 25 mEq/L

Fractional Excretion of Potassium (FEK)

Formula: FEK (%) = (Urine K+ × Plasma Cr) / (Plasma K+ × Urine Cr) × 100

Interpretation:

• FEK less than 10-15%: Renal K+ retention (appropriate response to hyperkalemia)
• FEK > 15-20%: Renal K+ wasting (extrarenal cause of hyperkalemia)

Etiology-Specific Testing

---

Treatment and Management

Treatment Principles

Hyperkalemia management follows a THREE-STEP APPROACH [4,9,10]:

1. PROTECT the heart (Membrane stabilization with calcium)
2. SHIFT K+ into cells (Insulin-dextrose, β-agonists, bicarbonate if acidotic)
3. REMOVE K+ from body (Diuretics, GI binders, dialysis)

Critical Concepts:

• Treatments work on different timescales - use multiple modalities concurrently
• Calcium does NOT lower K+ - only protects myocardium
• Shift therapies are temporary (K+ will redistribute back out) - must also remove K+
• Monitor closely - rebound hyperkalemia is common

Step 1: Membrane Stabilization (FIRST-LINE for ECG changes)

Calcium Salts [2,28]

Indications:

• ANY ECG changes attributable to hyperkalemia
• K+ > 6.5 mEq/L even without ECG changes (some protocols)
• Symptomatic hyperkalemia (muscle weakness)

Calcium Gluconate (FIRST CHOICE)

Calcium Chloride (ALTERNATIVE - Central line preferred)

Special Considerations:

• Digoxin toxicity: Use calcium with EXTREME caution - may precipitate severe arrhythmias ("stone heart"). Use half-dose (5 mL) slowly over 10-20 minutes, or avoid entirely. [31]
• Hypercalcemia: Relative contraindication (but ECG changes trump this concern)
• Monitor: Continuous cardiac monitoring during and for 30-60 min after administration

Mechanism: Stabilizes cardiac membrane by increasing threshold potential - does NOT affect serum K+

Step 2: Shift Potassium Intracellularly (Start IMMEDIATELY after calcium)

A. Insulin-Dextrose [11,32]

MOST RELIABLE and EFFECTIVE shifting therapy

Standard Protocol:

Alternative Protocol (if hyperglycemic, glucose > 250 mg/dL):

• Give insulin 10 units IV without dextrose
• Monitor glucose closely every 15-30 min

CRITICAL - Hypoglycemia Monitoring:

• Check glucose at 0, 15, 30, 60, 90, 120 minutes, then every 2 hours × 6 hours
• Hypoglycemia occurs in 10-30% of patients despite dextrose [11]
• Risk factors: Renal failure, low body weight, malnutrition
• Treatment: D50 25-50 mL IV if glucose less than 70 mg/dL; may need continuous dextrose infusion

Mechanism: Insulin activates Na-K-ATPase → drives K+ into cells (skeletal muscle, liver)

B. β2-Adrenergic Agonists (Salbutamol/Albuterol) [33,34]

ADJUNCT therapy - use WITH insulin-dextrose for additive effect

Nebulized Route (PREFERRED):

Intravenous Route (if nebulized unavailable):

Combination Therapy (Insulin + Salbutamol): [12]

• Additive effect: Combined K+ reduction 1.2-1.4 mEq/L (greater than either alone)
• Recommended: Use both for severe hyperkalemia (K+ > 6.5 mEq/L)

Adverse Effects:

• Tachycardia (common) - usually well-tolerated
• Tremor (common)
• Myocardial ischemia (rare) - use caution in CAD, acute MI
• Hypokalemia (with repeated dosing)

Mechanism: β2-receptor activation → ↑ cAMP → stimulates Na-K-ATPase → K+ enters cells

C. Sodium Bicarbonate [13,35]

ONLY effective in patients with metabolic acidosis (pH less than 7.20)

Controversy: Bicarbonate is NO LONGER routinely recommended for non-acidotic patients (minimal effect) [13]

Mechanism: Corrects acidosis → H+ exits cells → K+ enters cells (in exchange)

Important: Does NOT work well in:

• Non-acidotic patients (pH > 7.20)
• Organic acidosis (lactic acidosis, ketoacidosis) - less effective than mineral acidosis

Adverse Effects:

• Volume overload (especially HF, renal failure)
• Metabolic alkalosis
• Hypocalcemia (ionized Ca decreases)
• Hypernatremia

Step 3: Remove Potassium from Body (START EARLY - delayed effect)

A. Loop Diuretics (If Adequate Renal Function) [36]

Indications: K+ > 6.0 mEq/L + adequate renal function (urine output > 0.5 mL/kg/hr)

Efficacy: Depends on:

• Baseline renal function (ineffective if GFR less than 20 mL/min)
• Volume status
• Concurrent RAAS inhibitor use

Adverse Effects: Volume depletion, hypokalemia (with excessive diuresis), ototoxicity (high doses)

B. Gastrointestinal Potassium Binders

Comparison of Potassium Binders [37,38,39]

Sodium Zirconium Cyclosilicate (Lokelma) [38]

FIRST-LINE GI binder for acute hyperkalemia (if available)

Advantages:

• Fastest onset of GI binders
• Well-tolerated (minimal GI side effects)
• No sorbitol needed
• Works throughout GI tract

Disadvantages:

• Expensive ($500-$700/month)
• Not available in all countries
• May bind other medications (separate by 2 hours)

Patiromer (Veltassa) [39]

BEST for chronic hyperkalemia management (not acute emergencies)

Advantages:

• Well-tolerated
• Allows continuation of RAAS inhibitors in CKD/HF patients
• No GI necrosis risk

Disadvantages:

• SLOW onset (not for acute management)
• Expensive
• Binds other medications - give other meds 3 hours before patiromer
• GI side effects (constipation, diarrhea, nausea) in 10-20%

Sodium Polystyrene Sulfonate (Kayexalate, SPS) [40]

CONTROVERSIAL - use with caution due to GI necrosis risk

Efficacy Controversy:

• Limited evidence of efficacy in acute hyperkalemia [40]
• Many "responses" may be due to concurrent therapies (insulin, dialysis)
• Rectal route may be slightly faster

SERIOUS ADVERSE EFFECTS:

• Colonic necrosis (especially with sorbitol) - FDA Black Box Warning [41]
• Intestinal obstruction/perforation
• Fecal impaction
• Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia)
• Volume overload (Na+ load: 4 mEq per 1 g resin)

Contraindications:

• Post-operative state (especially post-abdominal surgery)
• Ileus or bowel obstruction
• Recent GI surgery

Recommendation: Newer agents (lokelma, patiromer) preferred when available; SPS is legacy therapy

C. Hemodialysis (DEFINITIVE Treatment) [6,42]

MOST EFFECTIVE method for K+ removal

Indications for Urgent/Emergent Dialysis [6]:

Hemodialysis Efficacy:

Dialysis Prescription for Hyperkalemia:

• Blood flow rate: 300-400 mL/min
• Dialysate flow rate: 500-800 mL/min
• Dialysate K+: 0-1 mEq/L (K+-free or low-K+ bath)
• Duration: 3-4 hours minimum (longer if K+ > 8.0 mEq/L)

Post-Dialysis Rebound:

• K+ may rebound 0.5-1.0 mEq/L in 1-2 hours post-HD (ICF → ECF equilibration)
• Recheck K+ 1-2 hours after completing dialysis
• Continue medical management post-dialysis

Alternative RRT Modalities:

---

Monitoring and Disposition

Monitoring Parameters

During Acute Treatment:

Post-Stabilization:

• Daily K+ until stable × 2-3 days
• BMP daily
• Reassess etiology and risk factors

Disposition Criteria

Discharge Home (Outpatient Management)

Criteria (ALL must be met):

• K+ less than 6.0 mEq/L AND decreasing
• NO ECG changes
• Asymptomatic
• Reversible cause identified and corrected (e.g., medication stopped)
• Adequate renal function (Cr less than 2.0 mg/dL or at baseline)
• Reliable for follow-up

Discharge Instructions:

• Low-K+ diet education
• Medication reconciliation (stop RAAS inhibitors, NSAIDs)
• Follow-up with PCP or nephrology within 3-7 days
• Recheck K+ and BMP in 3-5 days
• Return precautions (weakness, palpitations, dyspnea)

Hospital Admission (General Ward)

Criteria (ANY):

• K+ 6.0-6.5 mEq/L (not rapidly improving)
• Moderate hyperkalemia with unclear etiology
• AKI requiring monitoring
• Need for ongoing K+-lowering therapy
• Comorbidities complicating management (CKD, HF)
• Social factors (unreliable follow-up, homeless)

ICU Admission

Criteria (ANY):

• K+ > 6.5 mEq/L OR ANY ECG changes
• Wide QRS, sine wave, or arrhythmia
• Hemodynamic instability
• Need for urgent dialysis
• Symptomatic hyperkalemia (weakness, paralysis)
• Refractory hyperkalemia despite therapy
• Concurrent critical illness (DKA, tumor lysis syndrome, rhabdomyolysis)

---

Prevention and Long-Term Management

Dietary Potassium Restriction

Goal: less than 2-3 g (50-75 mEq) potassium per day for at-risk patients [43]

High-Potassium Foods to AVOID (> 200 mg K+ per serving):

Cooking Tip: Leaching vegetables reduces K+ by 50-75% (dice, soak in water 2-4 hours, discard water, cook in fresh water)

Medication Management

Stop or Reduce K+-Raising Medications [21,25]:

Risk-Benefit Consideration:

• RAAS inhibitors provide significant mortality benefit in CKD, HF, post-MI
• Discontinuation increases mortality [21]
• Goal: Use potassium binders (patiromer, lokelma) to allow continuation of RAAS inhibitors at optimal dose

Chronic Potassium Binder Therapy

For patients requiring RAAS inhibitors with recurrent hyperkalemia [37,38,39]:

Evidence: Chronic binder use allows 70-90% of patients to continue RAAS inhibitors [39]

Follow-Up Monitoring

For patients at risk of recurrent hyperkalemia:

---

Special Populations and Scenarios

Chronic Kidney Disease and Dialysis Patients

CKD Stage 4-5 (GFR less than 30 mL/min):

• High baseline risk of hyperkalemia
• RAAS inhibitors often needed but cause hyperkalemia
• Use chronic binders (patiromer, lokelma) to allow RAAS continuation [39]
• Strict dietary K+ restriction essential

Hemodialysis Patients:

• Hyperkalemia most common between dialysis sessions (day 2-3 after HD)
• Typical pre-dialysis K+ 4.5-6.0 mEq/L
• Emergency dialysis if K+ > 6.5 mEq/L with ECG changes or > 7.0 mEq/L
• Dietary non-compliance is most common cause

Diabetic Ketoacidosis (DKA)

Paradox: Total body K+ is DEPLETED despite initial hyperkalemia [44]

Mechanism:

• Insulin deficiency → K+ shifts OUT of cells → hyperkalemia
• Osmotic diuresis → massive renal K+ losses (total body depletion)
• With insulin therapy → K+ shifts INTO cells → severe hypokalemia

Management:

1. Check admission K+:
   • K+ less than 3.3 mEq/L: DO NOT start insulin until K+ > 3.3 (give K+ replacement)
   • K+ 3.3-5.0 mEq/L: Start insulin + give 20-30 mEq K+ per liter of IV fluid
   • K+ > 5.0 mEq/L: Start insulin; hold K+ supplementation initially
2. Monitor K+ every 2 hours during insulin infusion
3. Expect K+ to drop 0.5-1.0 mEq/L per hour with insulin therapy
4. Add K+ to IV fluids when K+ less than 5.0 mEq/L (usually within 2-4 hours)

Tumor Lysis Syndrome (TLS)

Definition: Massive cell lysis after chemotherapy → release of intracellular contents [45]

Electrolyte Abnormalities (classic triad + uric acid):

• Hyperkalemia
• Hyperphosphatemia
• Hypocalcemia (due to Ca-PO4 precipitation)
• Hyperuricemia → AKI

Management:

1. Prevention (high-risk patients):
   • IV hydration 2-3 L/m²/day
   • Allopurinol or rasburicase
   • Avoid nephrotoxins
2. Treatment:
   • Aggressive hydration
   • Insulin-dextrose, salbutamol for K+
   • Urgent hemodialysis for severe hyperkalemia + AKI (most effective)
   • Avoid calcium if hyperphosphatemia present (risk of Ca-PO4 precipitation)

Rhabdomyolysis

Mechanism: Muscle necrosis → K+ release (also myoglobin → AKI) [46]

Management:

1. Aggressive IV hydration (goal urine output 200-300 mL/hr)
2. Treat hyperkalemia (insulin-dextrose, salbutamol)
3. Alkalinize urine if severe (Na bicarbonate) - prevents myoglobin precipitation
4. Hemodialysis for severe hyperkalemia + AKI + volume overload

---

Evidence-Based Controversies and Updates

1. Sodium Bicarbonate Efficacy

Traditional Teaching: Bicarbonate lowers K+ by correcting acidosis

Modern Evidence: Multiple studies show no significant K+ reduction with bicarbonate in non-acidotic patients [13]

Recommendation: Reserve for pH less than 7.20; do NOT use routinely

2. Sodium Polystyrene Sulfonate (Kayexalate) Safety

Controversy: Efficacy questioned; serious GI adverse events [40,41]

Evidence:

• Efficacy: Modest K+ reduction (0.5-1.0 mEq/L); unclear if better than placebo
• Safety: FDA Black Box Warning for colonic necrosis (especially with sorbitol)
• Alternatives: Patiromer and lokelma are safer and more effective

Recommendation: Use newer agents when available; avoid SPS with sorbitol

3. Calcium in Digoxin Toxicity

Traditional Teaching: Calcium is contraindicated in digoxin toxicity ("stone heart")

Modern Evidence: Case reports only; no prospective data [31]

Recommendation:

• Use calcium with caution in digoxin toxicity
• Give slowly (10-20 min infusion) at half-dose (5 mL Ca gluconate)
• Continuous cardiac monitoring
• If life-threatening hyperkalemia (K+ > 7.5 or wide QRS), benefits outweigh risks

4. Routine Repeat Calcium Dosing

Question: Should calcium be re-dosed prophylactically every 30-60 min?

Evidence: No data to support routine repeat dosing [2]

Recommendation: Repeat calcium ONLY if:

• ECG changes persist after 5 minutes
• ECG changes recur
• K+ remains > 6.5 mEq/L with ongoing risk

---

Key Clinical Pearls

Diagnostic Pearls

1. ECG is more important than K+ level - treat ECG changes aggressively even if K+ is "only" 6.0 mEq/L [8]
2. Peaked T waves are the earliest sign - look in V2-V4; compare to prior ECG [1]
3. Wide QRS is ominous - impending cardiac arrest; treat as emergency [29]
4. Absence of ECG changes does NOT exclude severe hyperkalemia - 20-30% of patients with K+ > 7.0 have normal ECG [8]
5. Pseudohyperkalemia is common - repeat if unexpected; send plasma K+ if high suspicion [5]
6. Check glucose, renal function, acid-base status - affects K+ distribution and treatment

Treatment Pearls

1. Calcium does NOT lower K+ - only stabilizes cardiac membrane; must also shift/remove K+ [2]
2. Start all therapies concurrently - they work on different timescales (calcium: minutes; insulin: 30 min; dialysis: hours) [4]
3. Insulin-dextrose is most reliable - 75-100% response rate vs. 60-80% for salbutamol [11,33]
4. Combine insulin + salbutamol for additive effect - reduces K+ by 1.2-1.4 mEq/L [12]
5. Monitor glucose closely after insulin - hypoglycemia occurs in 10-30% despite dextrose [11]
6. Bicarbonate only works if acidotic (pH less than 7.20) - do NOT use routinely [13]
7. Dialysis is definitive - most effective K+ removal; use early in severe/refractory cases [6]
8. Beware rebound hyperkalemia - K+ redistributes from ICF after shift therapies wear off [4]
9. Stop offending medications - especially RAAS inhibitors, NSAIDs [25]
10. Use modern binders (lokelma, patiromer) instead of Kayexalate - safer and more effective [38,39,40]

Disposition Pearls

1. Admit for K+ > 6.0 or any ECG changes - even if responsive to therapy [3]
2. ICU for K+ > 6.5, wide QRS, or symptomatic hyperkalemia [3]
3. Arrange urgent dialysis access if needed - do NOT delay for repeat labs
4. Medication reconciliation is essential - stop K+-raising drugs; educate patient [25]
5. Low-K+ diet counseling - dietitian referral before discharge [43]
6. Close follow-up - recheck K+ in 3-5 days after discharge [30]

---

Clinical Decision Tools and Algorithms

Hyperkalemia Management Algorithm

HYPERKALEMIA CONFIRMED (K+ > 5.5 mEq/L)
         ↓
    Check ECG IMMEDIATELY
         ↓
         ├─→ ECG CHANGES PRESENT? ────────→ YES → EMERGENCY
         │   (Peaked T, wide QRS, etc.)           │
         │                                        ↓
         │                              1. CALCIUM gluconate 10 mL IV
         │                              2. Continuous cardiac monitoring
         │                              3. START ALL THERAPIES CONCURRENTLY:
         │                                 • Insulin 10 U + D50 25-50 g IV
         │                                 • Salbutamol 10-20 mg nebulized
         │                                 • Furosemide 40-80 mg IV (if UOP adequate)
         │                                 • Lokelma 10 g PO TID or patiromer
         │                              4. PREPARE FOR DIALYSIS if:
         │                                 • K+ > 6.5 + ECG changes persist
         │                                 • K+ > 8.0
         │                                 • Refractory to medical therapy
         │                              5. ICU ADMISSION
         │
         └─→ NO ECG CHANGES → Assess K+ Level
                    ↓
              K+ 5.5-6.0 mEq/L          K+ 6.0-6.5 mEq/L           K+ > 6.5 mEq/L
                    ↓                           ↓                         ↓
             • Identify cause          • Insulin-dextrose         • Treat as EMERGENCY
             • Stop K+-raising meds    • Salbutamol               (see above)
             • Low-K+ diet            • Furosemide
             • Consider binder         • GI binder
             • Repeat K+ in 2-4 hr     • Admit to floor
             • Outpatient F/U if       • Serial K+ monitoring
               reversible cause        • Repeat K+ q1-2h

---

Quality Metrics and Performance Indicators

Process Measures

Outcome Measures

Documentation Requirements

Essential Documentation:

1. Initial K+ level and time
2. ECG interpretation (specific findings)
3. Treatments given (drug, dose, time)
4. Response to treatment (repeat K+, ECG)
5. Etiology identified
6. Medications stopped/adjusted
7. Disposition plan
8. Follow-up arranged (date, provider)
9. Patient education provided (diet, medications)

---

Patient Education

Key Messages for Patients

What is hyperkalemia?

• "Your potassium level is too high. Potassium is a mineral that helps your heart and muscles work properly."
• "Too much potassium can cause dangerous heart rhythms that can be life-threatening."

Why did this happen?

• "Your kidneys normally remove extra potassium from your body. When kidney function is reduced, potassium can build up."
• "Some medications and foods high in potassium can also raise your level."

How are we treating this?

• "We're giving you medications to protect your heart and move potassium out of your blood and into your cells."
• "We're also giving treatments to help your body eliminate the extra potassium."
• "In some cases, dialysis (kidney machine) is needed to remove potassium quickly."

What do I need to do?

• Avoid high-potassium foods: Bananas, oranges, tomatoes, potatoes, salt substitutes
• Stop certain medications: Your doctor will review which medications to stop
• Follow up closely: You need blood tests in 3-5 days
• Return immediately if you develop: muscle weakness, palpitations, chest pain, trouble breathing

Dietary Education

Low-Potassium Diet (less than 2000 mg/day):

CHOOSE (Low-K+ foods):

• Apples, berries, grapes, watermelon
• Green beans, carrots, corn, cauliflower, lettuce
• White bread, white rice, pasta
• Chicken, fish, eggs (moderate portions)

AVOID (High-K+ foods):

• Bananas, oranges, melons, dried fruits
• Potatoes, tomatoes, spinach, avocado
• Beans, nuts
• Salt substitutes (contain KCl)
• Sports drinks (many contain K+)

Cooking Tips:

• Leach vegetables: Peel, dice, soak in water 2-4 hours, drain, cook in fresh water (removes 50-75% K+)
• Limit portion sizes of high-protein foods
• Read food labels (look for potassium content)

---

References

1. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3(2):324-330. doi:10.2215/CJN.04611007 [PMID: 18235143]

2. Long B, Warix JR, Koyfman A. Controversies in Management of Hyperkalemia. J Emerg Med. 2018;55(2):192-205. doi:10.1016/j.jemermed.2018.04.004 [PMID: 29731287]

3. Álvarez-Rodríguez E, Olaizola Mendibil A, San Martín Díez MLÁ, et al. Recommendations for the management of hyperkalemia in the emergency department. Emergencias. 2022;34(4):287-297. [PMID: 35833768]

4. Maxwell AP, Linden K, O'Donnell S, Hamilton PK, McVeigh GE. Management of hyperkalaemia. J R Coll Physicians Edinb. 2013;43(3):246-251. doi:10.4997/JRCPE.2013.312 [PMID: 24087806]

5. Asirvatham JR, Moses V, Bjornson L. Errors in potassium measurement: a laboratory perspective for the clinician. N Am J Med Sci. 2013;5(4):255-259. doi:10.4103/1947-2714.110426 [PMID: 23724401]

6. Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical Management of Hyperkalemia. Mayo Clin Proc. 2021;96(3):744-762. doi:10.1016/j.mayocp.2020.06.014 [PMID: 33012354]

7. Bakris G, Agiro A, Mu F, et al. Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality. JACC Adv. 2024;3(11):101331. doi:10.1016/j.jacadv.2024.101331 [PMID: 39741643]

8. Wrenn KD, Slovis CM, Slovis BS. The ability of physicians to predict electrolyte deficiency from the ECG. Ann Emerg Med. 1990;19(5):580-583. doi:10.1016/s0196-0644(05)82192-3 [PMID: 2331099]

9. Moussavi K, Fitter S, Gabrielson SW, Koyfman A, Long B. Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician. J Emerg Med. 2019;57(1):36-42. doi:10.1016/j.jemermed.2019.03.043 [PMID: 31084947]

10. Gupta AA, Self M, Mueller M, Wardi G, Tainter C. Dispelling myths and misconceptions about the treatment of acute hyperkalemia. Am J Emerg Med. 2022;52:85-91. doi:10.1016/j.ajem.2021.11.030 [PMID: 34890894]

11. Harel Z, Kamel KS. Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review. PLoS One. 2016;11(5):e0154963. doi:10.1371/journal.pone.0154963 [PMID: 27152941]

12. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38(5):869-872. doi:10.1038/ki.1990.284 [PMID: 2266669]

13. Blumberg A, Weidmann P, Shaw S, Gnädinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85(4):507-512. doi:10.1016/s0002-9343(88)80086-4 [PMID: 3052050]

14. Viera AJ, Wouk N. Potassium Disorders: Hypokalemia and Hyperkalemia. Am Fam Physician. 2015;92(6):487-495. [PMID: 26371733]

15. Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis. 2010;56(2):387-393. doi:10.1053/j.ajkd.2010.05.014 [PMID: 20599305]

16. Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014;10(2):251-257. doi:10.5114/aoms.2014.42577 [PMID: 24904657]

17. Kovesdy CP. Updates in hyperkalemia: Outcomes and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):41-47. doi:10.1007/s11154-016-9384-x [PMID: 27600582]

18. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212-220. [PMID: 26619087]

19. Paice BJ, Paterson KR, Onyanga-Omara F, Donnelly T, Gray JM, Lawson DH. Record linkage study of hypokalaemia in hospitalized patients. Postgrad Med J. 1986;62(725):187-191. doi:10.1136/pgmj.62.725.187 [PMID: 3714696]

20. An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16(6):R225. doi:10.1186/cc11872 [PMID: 23171442]

21. Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study. Am J Kidney Dis. 2022;80(2):164-173.e1. doi:10.1053/j.ajkd.2022.01.002 [PMID: 35085685]

22. Krogager ML, Torp-Pedersen C, Mortensen RN, et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J. 2017;38(2):104-112. doi:10.1093/eurheartj/ehw129 [PMID: 27141095]

23. Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med. 2017;84(12):934-942. doi:10.3949/ccjm.84a.17056 [PMID: 29244658]

24. Gumz ML, Rabinowitz L, Wingo CS. An Integrated View of Potassium Homeostasis. N Engl J Med. 2015;373(1):60-72. doi:10.1056/NEJMra1313341 [PMID: 26132942]

25. Whitlock R, Leon SJ, Manacsa H, et al. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2023;38(11):2503-2516. doi:10.1093/ndt/gfad101 [PMID: 37309038]

26. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6(7):e005428. doi:10.1161/JAHA.116.005428 [PMID: 28701505]

27. Adrogue HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med. 1981;71(3):456-467. doi:10.1016/0002-9343(81)90182-0 [PMID: 7025622]

28. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246-3251. doi:10.1097/CCM.0b013e31818f222b [PMID: 18936701]

29. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J. 2006;33(1):40-47. [PMID: 16572868]

30. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018 [PMID: 31706619]

31. Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40(1):41-46. doi:10.1016/j.jemermed.2010.02.011 [PMID: 20378296]

32. Allon M, Shanklin N. Effect of albuterol treatment on subsequent dialytic potassium removal. Am J Kidney Dis. 1995;26(4):607-613. doi:10.1016/0272-6386(95)90597-9 [PMID: 7573015]

33. Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? How safe? Chest. 1999;115(3):617-622. doi:10.1378/chest.115.3.617 [PMID: 10084467]

34. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant. 2003;18(11):2215-2218. doi:10.1093/ndt/gfg323 [PMID: 14551347]

35. Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: something old, something new. Kidney Int. 2016;89(3):546-554. doi:10.1016/j.kint.2015.11.018 [PMID: 26880452]

36. Halperin ML, Kamel KS. Potassium. Lancet. 1998;352(9122):135-140. doi:10.1016/S0140-6736(98)85044-7 [PMID: 9672294]

37. Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014;9(12):e114686. doi:10.1371/journal.pone.0114686 [PMID: 25489743]

38. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. Clin J Am Soc Nephrol. 2019;14(6):798-809. doi:10.2215/CJN.12651018 [PMID: 31076425]

39. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211-221. doi:10.1056/NEJMoa1410853 [PMID: 25415805]

40. Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6(6):CD013165. doi:10.1002/14651858.CD013165.pub2 [PMID: 32588430]

41. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of rare but serious harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation. Published December 11, 2014.

42. Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? Nephrol Dial Transplant. 2012;27(12):4294-4297. doi:10.1093/ndt/gfs293 [PMID: 22942173]

43. St-Jules DE, Goldfarb DS, Sevick MA. Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients? J Ren Nutr. 2016;26(5):282-287. doi:10.1053/j.jrn.2016.02.005 [PMID: 27046071]

44. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343. doi:10.2337/dc09-9032 [PMID: 19564476]

45. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854. doi:10.1056/NEJMra0904569 [PMID: 21561350]

46. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62-72. doi:10.1056/NEJMra0801327 [PMID: 19571284]

---

Summary

Hyperkalemia is a life-threatening electrolyte emergency that kills by cardiac arrhythmia. ECG changes are more prognostically important than absolute potassium level and require immediate treatment. Management follows a three-step approach: (1) membrane stabilization with calcium gluconate, (2) transcellular potassium shift with insulin-dextrose and β-agonists, and (3) total body potassium removal with diuretics, GI binders, or hemodialysis. Treatment modalities work on different timescales and should be initiated concurrently for severe hyperkalemia. Calcium protects the myocardium but does not lower potassium. Insulin-dextrose is the most reliable shift therapy but requires glucose monitoring to prevent hypoglycemia. Hemodialysis is the definitive treatment for severe or refractory hyperkalemia. Common causes include renal failure, RAAS inhibitors, tissue breakdown, and transcellular shifts from acidosis or insulin deficiency. Pseudohyperkalemia from hemolyzed samples must be excluded. Long-term management involves dietary potassium restriction, medication adjustment, and use of modern potassium binders (patiromer, sodium zirconium cyclosilicate) to allow continuation of beneficial RAAS inhibitor therapy.